Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages

Contrast Media and Molecular Imaging

Volumn 9, Issue 5, 2014, Pages 372-382

  Sigalov, Alexander B ^a  

^a SignaBlok Inc   (United States)

Author keywords

Apolipoprotein A I; Atherosclerosis; Biomimetic peptide; Gadolinium; Lipoprotein nanoparticle; Macrophage; Magnetic resonance imaging; Oxidation; Vulnerable plaque

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; GADOLINIUM; HIGH DENSITY LIPOPROTEIN; METHIONINE; CONTRAST MEDIUM; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONFOCAL LASER MICROSCOPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; WESTERN DIET; ANIMAL; CELL TRACKING; CHEMISTRY; CONFOCAL MICROSCOPY; METABOLISM; PROCEDURES; RADIOGRAPHY;

ANIMALS; CELL TRACKING; CONTRAST MEDIA; GADOLINIUM; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES;

EID: 84907987736     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1587     Document Type: Article

References (59)

1. Michaud CM, Murray CJ, Bloom BR. Burden of disease - implications for future research. Jama 2001; 285(5): 535-539.
2. Shah PK. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis 2002; 44(5): 357-368.
3. Bhatia V, Bhatia R, Dhindsa S, Virk A. Vulnerable plaques, inflammation and newer imaging modalities. J Postgrad Med 2003; 49(4): 361-368.
4. Sharif F, Murphy RT. Current status of vulnerable plaque detection. Catheter Cardiovasc Interven 2010; 75(1): 135-144.
5. Schaar JA, Mastik F, Regar E, den Uil CA, Gijsen FJ, Wentzel JJ, Serruys PW, van der Stehen AF. Current diagnostic modalities for vulnerable plaque detection. Curr Pharm Des 2007; 13(10): 995-1001.
6. Choudhury RP, Lee JM, Greaves DR. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2005; 2(6): 309-315.
7. Lusis AJ. Atherosclerosis. Nature 2000; 407(6801): 233-241.
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med 2005; 352(16): 1685-1695.
9. Wakhloo AK, Lieber BB, Seong J, Sadasivan C, Gounis MJ, Miskolczi L, Sandhu JS. Hemodynamics of carotid artery atherosclerotic occlusive disease. J Vasc Interven Radiol 2004; 15(1 Pt 2): S111-121.
10. MacNeill BD, Jang IK, Bouma BE, Iftimia N, Takano M, Yabushita H, Shishkov M, Kauffman CR, Houser SL, Aretz HT, DeJoseph D, Halpern EF, Tearney GJ. Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J Am Coll Cardiol 2004; 44(5): 972-979.
11. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90(2): 775-778.
12. Davies JR, Rudd JH, Weissberg PL. Molecular and metabolic imaging of atherosclerosis. J Nucl Med 2004; 45(11): 1898-1907.
13. Rudd JH, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29(7): 1009-1016.
14. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 2008; 451(7181): 953-957.
15. Choudhury RP, Fisher EA. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol 2009; 29(7): 983-991.
16. Lutz AM, Seemayer C, Corot C, Gay RE, Goepfert K, Michel BA, Marincek B, Gay S, Weishaupt D. Detection of synovial macrophages in an experimental rabbit model of antigen-induced arthritis: ultrasmall superparamagnetic iron oxide-enhanced MR imaging. Radiology 2004; 233(1): 149-157.
17. Collins DJ, Padhani AR. Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Magn 2004; 23(5): 65-83.
18. Veldhuis WB, Floris S, van der Meide PH, Vos IM, de Vries HE, Dijkstra CD, Bar PR, Nicolay K. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J Cereb Blood Flow Metab 2003; 23(9): 1060-1069.
19. Rothblat GH, Mahlberg FH, Johnson WJ, Phillips MC. Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. J Lipid Res 1992; 33(8): 1091-1097.
20. Jonas A. Reconstitution of high-density lipoproteins. Meth Enzymol 1986; 128: 553-582.
21. Rui M, Guo W, Ding Q, Wei X, Xu J, Xu Y. Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver. Int J Nanomed 2012; 7: 3751-3768.
22. Chen W, Vucic E, Leupold E, Mulder WJ, Cormode DP, Briley-Saebo KC, Barazza A, Fisher EA, Dathe M, Fayad ZA. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imag 2008; 3(6): 233-242.
23. Cormode DP, Briley-Saebo KC, Mulder WJ, Aguinaldo JG, Barazza A, Ma Y, Fisher EA, Fayad ZA. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008; 4(9): 1437-1444.
24. Frias JC, Lipinski MJ, Lipinski SE, Albelda MT. Modified lipoproteins as contrast agents for imaging of atherosclerosis. Contrast Media Mol Imag 2007; 2(1): 16-23.
25. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett 2006; 6(10): 2220-2224.
26. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004; 126(50): 16316-16317.
27. Lipinski MJ, Frias JC, Amirbekian V, Briley-Saebo KC, Mani V, Samber D, Abbate A, Aguinaldo JG, Massey D, Fuster V, Vetrovec GW, Fayad ZA. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imag 2009; 2(5): 637-647.
28. Mulder WJ, Strijkers GJ, Briley-Saboe KC, Frias JC, Aguinaldo JG, Vucic E, Amirbekian V, Tang C, Chin PT, Nicolay K, Fayad ZA. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med 2007; 58(6): 1164-1170.
29. Sauer I, Nikolenko H, Keller S, Abu Ajaj K, Bienert M, Dathe M. Dipalmitoylation of a cellular uptake-mediating apolipoprotein E-derived peptide as a promising modification for stable anchorage in liposomal drug carriers. Biochim Biophys Acta 2006; 1758(4): 552-561.
30. Wang XS, Gruenstein E. Rapid elevation of neuronal cytoplasmic calcium by apolipoprotein E peptide. J Cell Physiol 1997; 173(1): 73-83.
31. Tolar M, Keller JN, Chan S, Mattson MP, Marques MA, Crutcher KA. Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. J Neurosci 1999; 19(16): 7100-7110.
32. Anantharamaiah GM, Hughes TA, Iqbal M, Gawish A, Neame PJ, Medley MF, Segrest JP. Effect of oxidation on the properties of apolipoproteins A-I and A-II. J Lipid Res 1988; 29(3): 309-318.
33. von Eckardstein A, Walter M, Holz H, Benninghoven A, Assmann G. Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III. J Lipid Res 1991; 32(9): 1465-1476.
34. Sigalov AB, Stern LJ. Enzymatic repair of oxidative damage to human apolipoprotein A-I. FEBS Lett 1998; 433(3): 196-200.
35. Sigalov AB, Petrichenko IE, Kolpakova GV. The ratio of non-oxidized/oxidized forms of apolipoprotein A-I can affect cholesterol efflux from human skin fibroblasts mediated by high density lipoprotein. Eur J Clin Chem Clin Biochem 1997; 35(5): 395-396.
36. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A 2008; 105(34): 12224-12229.
37. Pankhurst G, Wang XL, Wilcken DE, Baernthaler G, Panzenbock U, Raftery M, Stocker R. Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein. J Lipid Res 2003; 44(2): 349-355.
38. Sigalov AB, Stern LJ. Oxidation of methionine residues affects the structure and stability of apolipoprotein A-I in reconstituted high density lipoprotein particles. Chem Phys Lipids 2001; 113(1-2): 133-146.
39. Zhang WL, Gu X, Bai H, Yang RH, Dong CD, Liu JP. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharm 2010; 391(1-2): 313-321.
40. Skajaa T, Cormode DP, Falk E, Mulder WJ, Fisher EA, Fayad ZA. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30(2): 169-176.
41. Glickson JD, Lund-Katz S, Zhou R, Choi H, Chen IW, Li H, Corbin I, Popov AV, Cao W, Song L, Qi C, Marotta D, Nelson DS, Chen J, Chance B, Zheng G. Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Mol Imag 2008; 7(2): 101-110.
42. Lacko AG, Nair M, Prokai L, McConathy WJ. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv 2007; 4(6): 665-675.
43. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, Nair MP, Park YY, Sabnis N, Deavers MT, Lee JS, Ellis LM, Lopez-Berestein G, McConathy WJ, Prokai L, Lacko AG, Sood AK. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011; 13(4): 309-319.
44. Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res 2006; 47(2): 260-267.
45. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke 2005; 36(12): 2764-2772.
46. Sinusas AJ, Bengel F, Nahrendorf M, Epstein FH, Wu JC, Villanueva FS, Zahi A, Fayad ZA, Robert J, Gropler RJ. Multimodality cardiovascular molecular imaging, part I. Circul Cardiovasc Imag 2008; 1(3): 244-256.
47. Pan D, Caruthers SD, Chen J, Winter PM, Senpan A, Schmieder AH, Wickline SA, Lanza GM. Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Med Chem 2010; 2(3): 471-490.
48. Platt N, Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional? - The mouse's tale. J Clin Invest 2001; 108(5): 649-654.
49. Sigalov A, Alexandrovich O, Strizevskaya E. Large-scale isolation and purification of human apolipoproteins A-I and A-II. J Chromatogr 1991; 537(1-2): 464-468.
50. Bergt C, Marsche G, Panzenboeck U, Heinecke JW, Malle E, Sattler W. Human neutrophils employ the myeloperoxidase/hydrogen peroxide/chloride system to oxidatively damage apolipoprotein A-I. Eur J Biochem 2001; 268(12): 3523-3531.
51. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010; 23(3): 447-454.
52. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94(1): 437-444.
53. Chen W, Cormode DP, Vengrenyuk Y, Herranz B, Felg JE, Klink A, Mulder WJ, Fisher EA, Fayad ZA. Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression. JACC: Cardiovasc Imag 2013; 6(3): 373-384.
54. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, Fisher EA, Fayad ZA. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007; 104(3): 961-966.
55. Nakano T, Nagata A. Immunochemical detection of circulating oxidized high-density lipoprotein with antioxidized apolipoprotein A-I monoclonal antibody. J Lab Clin Med 2003; 141(6): 378-384.
56. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227(5259): 680-685.
57. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978; 87(1): 206-210.
58. Van Veldhoven PP, Mannaerts GP. Inorganic and organic phosphate measurements in the nanomolar range. Anal Biochem 1987; 161(1): 45-48.
59. Chen W, Jarzyna PA, van Tilborg GA, Nguyen VA, Cormode DP, Klink A, Griffioen AW, Randolph GJ, Fisher EA, Mulder WJ, Fayad ZA. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. Faseb J 2010; 24(6): 1689-1699.